Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
1.24 MUSD
−2.11USD
−68.97 MUSD
7.83 MUSD
About MOLECULAR PARTNERS N
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Employees (FY)
182
Founded
2004
FIGI
BBG010B7DHZ0
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
